We are live on ! Find out more
ASND icon

Ascendis Pharma A/S
ASND

65 hedge funds and large institutions have $1.22B invested in Ascendis Pharma A/S in 2017 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 21 increasing their positions, 14 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 12

50% more funds holding in top 10

Funds holding in top 10: 8 → 12 (+4)

50% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 14

17% more capital invested

Capital invested by funds: $1.04B → $1.22B (+$180M)

12% more funds holding

Funds holding: 58 → 65 (+7)

4.41% less ownership

Funds ownership: 88.3% → 83.9% (-4.4%)

Holders
65
Holders Change
+7
Holders Change %
+12.07%
% of All Funds
1.47%
Holding in Top 10
12
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+50%
% of All Funds
0.27%
New
19
Increased
21
Reduced
14
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$16.5M
2
BlackRock
BlackRock
New York
+$15.7M
3
CAM
Cormorant Asset Management
Massachusetts
+$10.9M
4
BBA
Baker Bros. Advisors
New York
+$9.82M
5
EAM
Eventide Asset Management
Massachusetts
+$4.65M

Top Sellers

1
LCM
Laurion Capital Management
New York
-$8.3M
2
JP Morgan Chase
JP Morgan Chase
New York
-$7.16M
3
VMI
VHCP Management II
New York
-$6.76M
4
DCM
Driehaus Capital Management
Illinois
-$3.6M
5
MWNA
Marshall Wace North America
New York
-$3.21M
Name Holding Trade Value Shares
Change 		Change in
Stake
DCM
26
DAFNA Capital Management
California
$4.99M +$1.91M +52,413 +73%
AC
27
Ascend Capital
California
$4.99M +$4.53M +124,618 New
Hudson Bay Capital Management
28
Hudson Bay Capital Management
Connecticut
$4.81M – – –
Alyeska Investment Group
29
Alyeska Investment Group
Illinois
$3.46M -$854K -23,500 -21%
Deutsche Bank
30
Deutsche Bank
Germany
$3.01M -$639K -17,587 -19%
PC
31
Polar Capital
United Kingdom
$3M +$2.73M +75,000 New
UONDDL
32
University of Notre Dame du Lac
Indiana
$2.96M +$2.68M +73,771 New
Morgan Stanley
33
Morgan Stanley
New York
$2.55M -$132K -3,640 -5%
AllianceBernstein
34
AllianceBernstein
Tennessee
$2.23M +$929K +25,540 +85%
LCM
35
Laurion Capital Management
New York
$2.2M -$8.3M -228,378 -81%
EU
36
Emory University
Georgia
$2.04M -$330K -9,063 -15%
Wells Fargo
37
Wells Fargo
California
$1.71M +$454K +12,480 +41%
AA
38
ALPS Advisors
Colorado
$1.61M +$304K +8,368 +26%
ECM
39
Endurant Capital Management
California
$1.51M +$745K +20,498 +118%
Geode Capital Management
40
Geode Capital Management
Massachusetts
$816K +$15.2K +418 +2%
California Public Employees Retirement System
41
California Public Employees Retirement System
California
$811K +$21K +577 +3%
TD Asset Management
42
TD Asset Management
Ontario, Canada
$773K +$702K +19,300 New
Adage Capital Partners
43
Adage Capital Partners
Massachusetts
$761K +$691K +19,000 New
State Street
44
State Street
Massachusetts
$739K -$10.7K -294 -2%
Victory Capital Management
45
Victory Capital Management
Texas
$696K +$437K +12,010 +224%
ProShare Advisors
46
ProShare Advisors
Maryland
$691K +$627K +17,250 New
Goldman Sachs
47
Goldman Sachs
New York
$650K +$590K +16,233 New
ARTA
48
A.R.T. Advisors
New York
$650K +$591K +16,243 New
Renaissance Technologies
49
Renaissance Technologies
New York
$621K -$654K -18,000 -54%
Northern Trust
50
Northern Trust
Illinois
$515K +$467K +12,857 New
1
2
3 4

ASND Hedge Fund Activity: Q4 2017 in Review

65 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q4 2017, worth a combined $1.22B — up 17% from $1.04B a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new ASND positions and 12 closed out — a net gain of 7 holders — while 21 added to existing stakes and 14 trimmed.

The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $16.5M. The largest seller was Laurion Capital Management, cutting an estimated $8.3M.

  • 65 institutional investors held Ascendis Pharma A/S (ASND) as of Q4 2017, up from 58 in Q3 2017.
  • Funds reported $1.22B of Ascendis Pharma A/S stock for Q4 2017, up 17% quarter-over-quarter.
  • 19 funds opened new Ascendis Pharma A/S positions in Q4 2017 and 12 closed out, a net change of +7 holders.
  • The largest Ascendis Pharma A/S buyer in Q4 2017 was T. Rowe Price Associates, an estimated $16.5M added.
  • The largest Ascendis Pharma A/S seller in Q4 2017 was Laurion Capital Management, an estimated $8.3M sold.

Based on aggregated 13F filings for Q4 2017.